Heart failure activates multiple neurohormonal systems (noradrenaline, renin, vasopressin, endothelin, BNP), and measuring these provides diagnostic, prognostic, and treatment-guiding information beyond standard clinical assessment.
Triple clinical utilityNeurohormones in heart failure provide diagnostic (what's wrong), prognostic (what will happen), and therapeutic (what to do) information simultaneously
What the researchers found
Heart failure involves coordinated activation of multiple neurohormonal systems, and measuring these provides diagnostic, prognostic, and therapeutic guidance, with BNP/NT-proBNP showing the strongest clinical utility.
Why it matters
Heart failure management increasingly relies on biomarker-guided therapy. Understanding which hormones to measure and what their levels mean improves clinical decision-making across the disease spectrum.
How the study worked
Comprehensive review of neuroendocrine activation in heart failure, covering pathophysiology, diagnostic utility, prognostic value, and treatment implications of multiple hormonal systems.
What this study cannot tell us
Review from 2001. Some neurohormonal targets described have not yet yielded successful therapies (vasopressin, endothelin in chronic HF). Treatment guidelines have evolved.
How to read the evidence
Moderate evidence from a comprehensive review integrating pathophysiological, diagnostic, and clinical trial data across multiple neurohormonal systems.
When this study was published
Published in 2001. The neurohormonal model of heart failure described here remains the dominant treatment paradigm, with all major drug classes targeting these systems.
The bigger picture
Modern heart failure treatment targets the specific neurohormonal systems described here: beta-blockers (noradrenaline), ACE inhibitors/ARBs (RAAS), MRA (aldosterone), and sacubitril (natriuretic peptides). This review maps the biological basis for the entire treatment armamentarium.
Questions still open
- Can a multi-marker panel replace clinical staging?
- Should therapy be guided by biomarker levels rather than symptoms?
- Which neurohormonal systems offer the best remaining therapeutic targets?
Common questions
Why do doctors measure so many hormones in heart failure?
How does this guide treatment?
Read the original research
Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.
Clinical physiology (Oxford, England), 21(6), 661-72
Citation
Kjaer, A; Hesse, B. (2001). Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.. Clinical physiology (Oxford, England), 21(6), 661-72.